» Articles » PMID: 23385734

Exploiting Inflammation for Therapeutic Gain in Pancreatic Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 2013 Feb 7
PMID 23385734
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, inflammatory signals are implicated in both tumour initiation and tumour progression. The major pathways regulating PDAC-associated inflammation are now being explored. Activation of leukocytes, and upregulation of cytokine and chemokine signalling pathways, both have been shown to modulate PDAC progression. Therefore, targeting inflammatory pathways may be of benefit as part of a multi-target approach to PDAC therapy. This review explores the pathways known to modulate inflammation at different stages of tumour development, drawing conclusions on their potential as therapeutic targets in PDAC.

Citing Articles

The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice.

Leal A, Liby K Int J Mol Sci. 2024; 25(18).

PMID: 39337472 PMC: 11432103. DOI: 10.3390/ijms25189985.


Advancements in Pancreatic Cancer Detection: Integrating Biomarkers, Imaging Technologies, and Machine Learning for Early Diagnosis.

Daher H, Punchayil S, Ismail A, Fernandes R, Jacob J, Algazzar M Cureus. 2024; 16(3):e56583.

PMID: 38646386 PMC: 11031195. DOI: 10.7759/cureus.56583.


Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment.

Amo-Aparicio J, Dominguez A, Atif S, Dinarello A, Azam T, Alula K Cancer Res Commun. 2023; 3(9):1899-1911.

PMID: 37772994 PMC: 10510589. DOI: 10.1158/2767-9764.CRC-23-0065.


The Oncologic Implications of Tumor Multiplicity in Intrahepatic Cholangiocarcinoma: Its Prognostic Value Might Be Underestimated.

Yoon S, Park S, Kim H, Shin S, Heo J, Rhu J Cancer Res Treat. 2023; 55(3):948-955.

PMID: 36915251 PMC: 10372597. DOI: 10.4143/crt.2023.290.


Estimating Metastatic Risk of Pancreatic Ductal Adenocarcinoma at Single-Cell Resolution.

Chen S, Zhou S, Huang Y, Yuan M, Lei W, Chen J Int J Mol Sci. 2022; 23(23).

PMID: 36499343 PMC: 9736800. DOI: 10.3390/ijms232315020.


References
1.
Neoptolemos J, Stocken D, Bassi C, Ghaneh P, Cunningham D, Goldstein D . Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304(10):1073-81. DOI: 10.1001/jama.2010.1275. View

2.
Bayne L, Beatty G, Jhala N, Clark C, Rhim A, Stanger B . Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012; 21(6):822-35. PMC: 3575028. DOI: 10.1016/j.ccr.2012.04.025. View

3.
Ochi A, Graffeo C, Zambirinis C, Rehman A, Hackman M, Fallon N . Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012; 122(11):4118-29. PMC: 3484447. DOI: 10.1172/JCI63606. View

4.
Frese K, Neesse A, Cook N, Bapiro T, Lolkema M, Jodrell D . nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012; 2(3):260-269. PMC: 4866937. DOI: 10.1158/2159-8290.CD-11-0242. View

5.
Provenzano P, Cuevas C, Chang A, Goel V, Von Hoff D, Hingorani S . Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3):418-29. PMC: 3371414. DOI: 10.1016/j.ccr.2012.01.007. View